Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: ciphergen + chooses + mosaic  Related to the article below (Last Update: 8/5/2008)

One Year After Acquisition, Caprion Still Eyes Sale to Rx ? But No ...
Proteo Monitor, NY - Jul 31, 2008
A few months before the Caprion Proteomics spinout, Ciphergen Biosystems, now called Vermillion, sold its SELDI platform to Bio-Rad Laboratories in order to ...
HistoRx Names Bill Sullivan Senior Vice President, Diagnostic ...
FOXBusiness - Jul 17, 2008
He was previously Vice President, Corporate Operations of Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.); prior to that, he served as Vice President ...
Stephen Pentoney, Joseph Hogan, John Dineen, Alan Fletcher ...
bioArray News (subscription), NY - Jul 22, 2008
Sullivan was VP of corporate development for Vermillion (previously Ciphergen), and he was VP of operations at Nichols Institute Diagnostics.ILMN
Hogan Steps Down as GE Healthcare Chief, Fletcher Joins ...
GenomeWeb News (subscription), NY - Jul 18, 2008
Sullivan was VP of corporate development for Vermillion (previously Ciphergen), and he was VP of operations at Nichols Institute Diagnostics. ...PKI
Learn about the World Biotechnology Instrumentation Market
Market Wire (press release) - Jul 7, 2008
... Agreement with Bruker Daltonics II-33 ESA Biosciences Purchases Richard Scientific II-33 Ciphergen Divests Life Science Research Business II-33 Furuno ...
Source: Google News

Mining mass spectra for diagnosis and biomarker discovery of cerebral accidents -
J Prados, A Kalousis, JC Sanchez, L Allard, O … - PROTEOMICS, 2004 - doi.wiley.com
... for these parameters, setting them manually through the Ciphergen ProteinChip software ...
for merging that satisfy the constraints the algorithm chooses the one ...

Quality control and peak finding for proteomics data collected from nipple aspirate fluid by surface … -
KR Coombes, HA Fritsche Jr, C Clarke, JN Chen, KA … - Clin Chem, 2003 - works.bepress.com
... arrays (Ciphergen Biosystems, Inc.) on 4 successive days to generate 24 SELDI spectra. ...
3 Ciphergen Biosystems, Inc., 6611 Dumbarton Circle, Fremont, CA 94555. ...

Annotated regions of significance of SELDI-TOF-MS spectra for detecting protein biomarkers. -
CS Tan, A Ploner, A Quandt, J Lehti?, M Pernemalm … - Proteomics, 2006 - doi.wiley.com
... TOF MS), Protein Biology System IIc (Ciphergen, CA, USA). ... The PCA-based algorithm
is less ad hoc and better in the sense that it automatically chooses the best ...

A new genetic algorithm in proteomics: Feature selection for SELDI-TOF data
C Reyn?s, R Sabatier, N Molinari, S Lehmann - Computational Statistics and Data Analysis, 2008 - Elsevier
... In our method, the baseline correction and the normalization (based on total ion
current) provided by Ciphergen ProteinChip ? software (Ciphergen Biosystems ...

A parsimonious threshold-independent protein feature selection method through the area under … -
Z Wang, YI Chang, Z Ying, L Zhu, Y Yang - Bioinformatics, 2007 - Oxford Univ Press
... Peak detection and alignment were operated with Ciphergen ProteinChip Software 3.0. ...
Moreover, on average, PTIFS method chooses 5.7 fewer features compared with ...

Heart disease, clinical proteomics and mass spectrometry -
BA Stanley - Disease Markers, 2002 - IOS Press
... However, if one chooses to use patient serum, the pa- tient to patient heterogeneity
can be overcome through (a) increasing the number of patients to be studied ...

Tabu Search Enhanced Markov Blanket Classifier for High Dimensional Data Sets -
X Bai, R Padman - Proceedings of INFORMS Computing Society.(to appear) Kluwer …, 2005 - Springer
... simplest form, Tabu Search starts with a feasible solution and chooses the best ... Peak
detection was performed using Ciphergen SELDI software versions 3.0 and 3.0 ...

TABU SEARCH ENHANCED MARKOV BLANKET CLASSIFIER FOR HIGH DIMENSIONAL DATA SETS
D SETS - The Next Wave in Computing, Optimization, and Decision …, 2005 - books.google.com
... simplest form, Tabu Search starts with a feasible solution and chooses the best ... Peak
detection was performed using Ciphergen SELDI software versions 3.0 and 3.0 ...
-

1 Q Statistical Design and Analytical Strategies for Discovery of Disease-Specific Protein Patterns
Z Feng, Y Yasui, D McLerran, BL Adam, J Semmes - Informatics in Proteomics, 2005 - books.google.com
... SELDI-TOF utilizes the ProteinChip Technology developed by Ciphergen Biosys- tems ...
the predictor after seeing the test set performance, or chooses a predictor ...
-

[PDF] Editor-in-Chief -
J Niklinski, J Lautermann, P Lehn, A Lukaszyk, B … - advms.pl
Page 1. 1 Contents Page 2. 2 Roczniki Akademii Medycznej w Bialymstoku 2005
(50) Suppl 1 J. Lautermann (Essen, Germany) P. Lehn (Paris ...

Source: Google Scholar
 
 

Ciphergen Chooses Mosaic To Develop Broad Reimbursement Strategy For Ovarian Tumor Triage Test

Article Date: 22 Dec 2006 - 0:00 PST
Ciphergen Biosystems, Inc. (Nasdaq: CIPH) today announced that it has teamed with Mosaic Health Care Consultants to develop reimbursement strategies and programs for its ovarian tumor triage test.

"The establishment of optimal reimbursement for our ovarian tumor diagnostic program is one crucial aspect of gaining rapid adoption by the medical community," said Gail S. Page, President and CEO of Ciphergen. "Mosaic is an ideal partner for us to work with given their extensive experience helping innovative healthcare diagnostic providers successfully secure reimbursement from public and private payers."

Mosaic specializes in reimbursement, health economics, and outcomes research for pharmaceutical, biotechnology, medical device, and diagnostics clients. Ciphergen and Mosaic will work together to build and implement strong reimbursement strategies and tactics.

"We are looking forward to helping ensure that this exciting high-value molecular diagnostic test receives the appropriate level of recognition from both the clinical and payer communities," said Peter Mazonson, M.D., Principal and Co-founder of Mosaic Health Care Consultants.

About Ciphergen's Ovarian Cancer Diagnostic Program

Ciphergen has an advanced diagnostic program in ovarian cancer and has developed a panel of biomarkers that provides risk stratification information for ovarian cancer based on a series of studies involving over 2,000 clinical samples from more than five sites. Ciphergen is undertaking a prospective clinical trial to support submission to the U.S. Food and Drug Administration for clearance as an in vitro diagnostic.

Ciphergen has a strategic alliance with Quest Diagnostics focused on commercializing the ovarian tumor triage test. Quest also has the option to develop and commercialize two additional Ciphergen tests.

In addition to developing a diagnostic test designed to distinguish between benign and malignant pelvic masses, studies are underway to predict recurrence of ovarian cancer and to provide additional tools to aid physicians in triaging women considered at high risk of ovarian cancer. Ciphergen's comprehensive diagnostic development program is being conducted with several leading collaborators at The Johns Hopkins School of Medicine, The University of Texas M.D. Anderson Cancer Center, University College London, and the University of Kentucky.

About Ovarian Cancer

Commonly known as the "silent killer," ovarian cancer leads to approximately 14,000 deaths each year in the United States. Approximately 23,000 new cases are diagnosed each year, with the majority in patients diagnosed with late stage disease where the cancer has spread beyond the ovary. The prognosis is poor in these patients, leading to the high mortality from this disease. A diagnostic test is needed that can provide adequate predictive value to stratify patients with a pelvic mass into high risk of invasive ovarian cancer versus those with low risk.

About Mosaic Health Care Consultants

Mosaic is a health care consulting firm specializing in reimbursement, health economics, and outcomes research for a wide spectrum of health care clients. Mosaic provides customers with the tools they need to demonstrate the clinical and economic utility of their products and to successfully secure reimbursement from public and private payers. Based in Larkspur, California, more information about Mosaic can be found on the web at http://www.mosaichealthcare.com.

Article continues below and (thank you)
 
About Ciphergen

Ciphergen Biosystems, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Ciphergen, along with its prestigious scientific collaborators, has ongoing diagnostic programs in oncology, cardiology and women's health with an initial focus in ovarian cancer. Based in Fremont, California, more information about Ciphergen can be found on the web at http://www.ciphergen.com.

Safe Harbor Statement

This press release contains forward-looking statements. For purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"), Ciphergen disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such forward-looking statements include statements regarding the impact of Ciphergen's efforts to obtain reimbursement for the company's ovarian tumor triage test. Actual results may differ materially from those projected in such forward-looking statements due to various factors, including the possibility that despite the efforts of the company and its partner, reimbursement may not be obtained as quickly as expected or at all. Investors should consult Ciphergen's filings with the Securities and Exchange Commission, including its Form 10-Q filed November 20, 2006, for further information regarding these and other risks related to the Company's business.

Ciphergen Biosystems, Inc.
http://www.ciphergen.com
 

Antibody Plus Chemotherapy Shows Efficacy In Mouse Ovarian Tumor Model

EA5, an antibody to a protein expressed by ovarian cancer cells, in combination with paclitaxel decreased the growth of ovarian cancer in a mouse model, according to a new study.

Anil K. Sood, M.D., of the University of Texas M.D. Anderson Cancer Center in Houston, and colleagues examined the effect of the EA5 monoclonal antibody, alone or in combination with the chemotherapeutic drug paclitaxel, on the growth of ovarian cancer cells in mice. Specifically, they were interested in assessing the effects of an oncoprotein called EphA2, the molecule EA5 targets, on cancer cell growth.

They found that ovarian cancer cells treated with EA5 had a 90% reduction in EphA2 expression. When used with paclitaxel, EA5 substantially reduced tumor weight and helped mice survive for longer periods of time.

Contact:
Scott Merville

###

Other highlights in the November 1 JNCI

Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jncicancerspectrum.oxfordjournals.org/.

Contact: Andrea Widener
Journal of the National Cancer Institute

 

 

Potential Ovarian Cancer Stem Cells Found By Mass. General Study



Massachusetts General Hospital (MGH) researchers have identified potential ovarian cancer stem cells, which may be behind the difficulty of treating these tumors with standard chemotherapy. Understanding more about the stem-like characteristics of these cells could lead to new approaches to treating ovarian cancer, which kills more than 16,000 U.S. women annually and is their fifth most common cause of cancer death. The report will appear in the July 25 Proceeding of the National Academy of Sciences (PNAS) and has received early online release.

"We feel these stem-like cancer cells may be resistant to traditional chemotherapy and could be responsible for the ultimately fatal drug-resistant recurrence that is characteristic of ovarian cancer," says Paul Szotek, MD, of the MGH Pediatric Surgical Research Laboratories, first author of the PNAS report. "We believe this likely is the first time stem-like cells have been found in models of ovarian cancer and in cells associated with human ovarian cancer."

Several recent studies have identified tiny populations of tumor cells that appear to act like stem cells, driving the tumor's ability to grow and spread. If some of these specialized cells escaped destruction by chemotherapy or radiation, the tumor would be able to recur quickly, often in a form resistant to chemotherapy. Similar cancer stem cells have been previously identified in leukemia and breast cancer and in cell lines of central nervous system and gastrointestinal tumors.

Standard treatment for ovarian cancer - surgical removal of all involved tissues followed by chemotherapy - usually appears successful, but treatment-resistant tumors recur in the vast majority of patients, leading to a five-year survival rate of less than 30 percent. Those factors and other observations suggested that cancer stem cells may also be found with ovarian tumors, leading to the current study.

The MGH researchers first examined two mouse ovarian cancer cell lines and identified cells with characteristics of the cancer stem cells found with other tumors. They then observed a small percentage of stem-like cells in human ovarian cancer lines and in cells taken from ascites fluid that had accumulated within the abdomen of several ovarian cancer patients. When mouse ovarian tumor stem-like cells were injected under the skin of mice, they led to the formation of new tumors much faster than did injections of regular tumor cells.

Although the potential ovarian cancer stem cells were less responsive than regular tumor cells to in vitro treatment with the chemotherapy drug doxorubicin, the stem-like cells remained sensitive to repeated treatment with Mullerian Inhibiting Substance (MIS). This protein, important in the normal development of sexual organs, has been studied for its potential to treat several reproductive tumors by Patricia Donahoe, MD, director of the MGH Pediatric Surgical Research Laboratories and senior author of the PNAS study, and David MacLaughlin, PhD, associate director of the labs and a study co-author.

"We feel that non-traditional, possibly innovative approaches will be required to eradicate these stem-like cancer cells and ultimately cure ovarian cancer. With its potential to maintain the ability to inhibit the proliferation of these cells, MIS may play a role in these new therapeutic approaches," Donahoe says. "We intend to keep searching for stem-like cells in patient tumor samples and to study their responsiveness to both chemotherapeutic agents and to novel agents specifically targeted to stem cell as individualized therapy of the future." Donahoe is the Marshall K. Bartlett Professor of Surgery at Harvard Medical School.

###

Additional co-authors of the PNAS study are Rafael Pieretti-Vanmarcke, MD, and Peter Masiakos, MD, MGH Pediatric Surgical Research Laboratories; Rosemary Foster, PhD, MGH Hematology/Oncology; David Dombkowski, and Frederic Preffer, PhD, MGH Center for Regenerative Medicine and Harvard Stem Cell Institute; Daniela Dinulescu, PhD, Brigham and Women's Hospital; and Denise Connolly, PhD, Fox Chase Cancer Center, Philadelphia. The work was supported by the Ruth Kirchestin National Research Service Award (T32 Cancer Biology Training Grant), the Burroughs Wellcome Fund, the National Institutes of Health, the U.S. Department of State, and contributions to the Pediatric Surgical Research Laboratories from the McBride Family and the W. Gerald Austen Funds.

Massachusetts General Hospital, established in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of nearly $500 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, transplantation biology and photomedicine. MGH and Brigham and Women's Hospital are founding members of Partners HealthCare System, a Boston-based integrated health care delivery system.

Contact: Sue McGreevey
Massachusetts General Hospital

 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News9A ;